药明康德
(603259)
| 流通市值：1534.56亿 | | | 总市值：1772.07亿 |
| 流通股本：25.01亿 | | | 总股本：28.88亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 9,654,595,304.28 | 39,241,431,359.88 | 27,702,002,254.76 | 17,240,918,263.02 |
| 营业收入 | 9,654,595,304.28 | 39,241,431,359.88 | 27,702,002,254.76 | 17,240,918,263.02 |
| 二、营业总成本 | 6,712,128,987.72 | 27,342,268,206.88 | 19,967,164,047.62 | 12,203,655,162.93 |
| 营业成本 | 5,574,529,171.26 | 22,964,515,460.62 | 16,440,256,129.17 | 10,453,936,890.44 |
| 税金及附加 | 84,736,857.59 | 301,181,005.49 | 218,784,249.97 | 146,876,170.27 |
| 销售费用 | 194,051,886.09 | 745,388,381.87 | 546,582,318.74 | 357,521,839.98 |
| 管理费用 | 562,794,264.61 | 2,879,341,988.34 | 1,869,468,114.84 | 1,212,235,637.14 |
| 研发费用 | 224,408,414.09 | 1,238,524,969.42 | 954,042,826.94 | 636,308,858.78 |
| 财务费用 | 71,608,394.08 | -786,683,598.86 | -61,969,592.04 | -603,224,233.68 |
| 其中:利息费用 | 65,761,071.64 | 216,033,816.34 | 150,222,876.33 | 107,053,052.78 |
| 其中:利息收入 | 204,414,638.64 | 626,757,006.25 | 467,311,764.91 | 316,477,649.99 |
| 加:公允价值变动收益 | -45,938,551.48 | 186,957,574.92 | 217,646,546.11 | -99,587,866.93 |
| 加:投资收益 | 1,537,653,139.2 | 604,162,381.66 | -164,809,637.05 | 22,379,410.5 |
| 资产处置收益 | -13,400,009.25 | -36,063,443.51 | -7,955,695.32 | -3,454,353.96 |
| 资产减值损失(新) | -156,213,198.67 | -1,236,257,969.76 | -20,104,426.49 | 11,412,652.34 |
| 信用减值损失(新) | -78,773,317.83 | -337,578,609.74 | -155,999,892.45 | -83,107,058.67 |
| 其他收益 | 106,954,396.76 | 499,791,631.57 | 287,254,161.42 | 193,548,192.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 4,292,748,775.29 | 11,580,174,718.14 | 7,890,869,263.36 | 5,078,454,076.27 |
| 加:营业外收入 | 152,777.95 | 22,254,764.5 | 5,586,936.32 | 4,035,872.06 |
| 减:营业外支出 | 13,008,002.36 | 62,617,843.56 | 42,160,110.47 | 32,936,177.98 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 4,279,893,550.88 | 11,539,811,639.08 | 7,854,296,089.21 | 5,049,553,770.35 |
| 减:所得税费用 | 564,424,709.84 | 1,972,072,099.9 | 1,252,684,573.24 | 768,708,087.44 |
| 六、净利润 | 3,715,468,841.04 | 9,567,739,539.18 | 6,601,611,515.97 | 4,280,845,682.91 |
| 持续经营净利润 | 3,733,866,312.31 | 11,396,829,426.64 | 6,601,611,515.97 | 4,280,845,682.91 |
| 终止经营净利润 | -18,397,471.27 | -1,829,089,887.46 | - | - |
| 归属于母公司股东的净利润 | 3,671,960,950.47 | 9,450,308,427.78 | 6,532,934,698.28 | 4,239,822,013.11 |
| 少数股东损益 | 43,507,890.57 | 117,431,111.4 | 68,676,817.69 | 41,023,669.8 |
| (一)基本每股收益 | 1.29 | 3.28 | 2.25 | 1.46 |
| (二)稀释每股收益 | 1.28 | 3.26 | 2.24 | 1.45 |
| 八、其他综合收益 | 118,473,436.43 | 185,718,884.52 | -3,353,834.76 | 14,733,694.61 |
| 归属于母公司股东的其他综合收益 | 120,103,150.04 | 188,583,091.93 | -3,156,713.02 | 17,103,453.09 |
| 九、综合收益总额 | 3,833,942,277.47 | 9,753,458,423.7 | 6,598,257,681.21 | 4,295,579,377.52 |
| 归属于母公司股东的综合收益总额 | 3,792,064,100.51 | 9,638,891,519.71 | 6,529,777,985.26 | 4,256,925,466.2 |
| 归属于少数股东的综合收益总额 | 41,878,176.96 | 114,566,903.99 | 68,479,695.95 | 38,653,911.32 |
| 公告日期 | 2025-04-29 | 2025-03-18 | 2024-10-29 | 2024-07-30 |
| 审计意见(境内) | | 标准无保留意见 | | |